San Diego-primarily based Viking Therapeutics marked alone as a serious competitor during the weight loss drug sector in February soon after revealing promising information from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection As well as in